Guggenheim Maintains Buy on MBX Biosciences, Raises Price Target to $150

Benzinga Newsdesk www.benzinga.com Positive 72.3%

Neg 0% Neu 0% Pos 72.3%

Guggenheim analyst Seamus Fernandez maintains MBX Biosciences (NASDAQ:MBX) with a Buy and raises the price target from $88 to $150.